


Experimental cancer vaccine shows promise in animal studies

November 10 2022

VAX-INNATE: Improving cancer vaccination by combining CD8⁺ T cell generation with systemic innate immune activation



Graphical abstract. Credit: *Cell* (2022). DOI: 10.1016/j.cell.2022.10.006

An experimental therapeutic cancer vaccine induced two distinct and desirable immune system responses that led to significant tumor regression in mice, report investigators from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The researchers found that intravenous (IV) administration of the vaccine boosted the number of cytotoxic T cells capable of infiltrating and attacking [tumor cells](#) and engaged the [innate immune system](#) by inducing type I interferon.

The [innate immune response](#) modified the [tumor microenvironment](#), counteracting suppressive forces that otherwise would tamp down T-cell action. Modification of the tumor microenvironment was not seen in mice that received the vaccine via needle injection into the skin (subcutaneous administration).

Dubbed "vax-innate" by the scientific team, the approach achieves an important goal in the quest for more effective immunotherapeutic vaccines for cancer. The study demonstrates that IV vaccine delivery enables and enhances T-cell immunity by overcoming tumor-induced immunosuppressive activity.

The researchers say the candidate vaccine might also be given intravenously to people who have already received tumor-specific T cells as a therapy. It also could improve tumor control by increasing the number of T cells and altering the tumor microenvironment to make them function better, the researchers note.

The experimental vaccine, SNAPvax, was designed by Robert Seder, M.D., and colleagues at the NIAID Vaccine Research Center (VRC) together with collaborators from Vaccitech North America, a clinical-stage biopharmaceutical company in Baltimore, Maryland. Vaccitech announced plans to advance the SNAPvax platform for use in treating human papilloma virus-associated cancer in 2023.

The research is published in *Cell*.

More information: Faezzah Baharom et al, Systemic vaccination induces CD8+ T cells and remodels the tumor microenvironment, *Cell* (2022). [DOI: 10.1016/j.cell.2022.10.006](https://doi.org/10.1016/j.cell.2022.10.006)

Provided by NIH/National Institute of Allergy and Infectious Diseases

Citation: Experimental cancer vaccine shows promise in animal studies (2022, November 10) retrieved 12 February 2024 from <https://medicalxpress.com/news/2022-11-experimental-cancer-vaccine-animal.html>

<p>This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.</p>
--